Sistemic Limited (Sistemic), the miRNA profiling company with facilities in Glasgow, Scotland and Boston, announced today the signature of an agreement to allow Progenitor Cell Therapy (PCT) to initiate evaluation studies on Sistemic’s SistemQC™ stem cell characterisation technology.
Dr. David Mallinson, Senior Staff scientist at Sistemic attended the World Stem Cell Summit in West Palm Beach, Florida, on December 3-5th 2012. We are thrilled to announce that David won the Best Poster of the many posters that were presented over the 3 days of the busy international meeting which was judged by a prestigious panel of Cell Therapy Experts. So well done David!
EMD Millipore, the Life Science division of Merck KGaA, Darmstadt, Germany, today announced a new initiative with Sistemic Ltd., a leading provider of microRNA-based problem-solving services and kit-based products.
Glasgow, SCOTLAND. Sistemic Ltd. is excited to announce significant progress with the development of a miRNA-based assay for assessment of pluripotent stem cell (PSC) contamination in derived cell therapy products. The development is being undertaken in conjunction with LGC, the UK National Measurement Laboratory and Designated Institute for chemical and bio-measurement.
Glasgow, Scotland Sistemic Ltd announced today the award of an Innovate UK grant to further develop, to a market-ready stage, its groundbreaking prototype microRNA-based assay for accurate assessment of pluripotent stem cell contamination in derived cell therapy products.
Sistemic Ltd. announced today the publication of its ground-breaking research, undertaken together with TiGenix, identifying a set of circulating miRNA biomarkers which could potentially be used, if further clinically validated, to stratify refractory rheumatoid arthritis patients, prior to treatment, into responders and non-responders to an allogenic cell-based therapy: